doi: 10.3389/fimmu.2025.1608262 Received 08 April 2025 Accepted 23 June 2025 Published 09 July 2025 Volume 16 - 2025 Edited by Xiaoli Liu, Jilin University, China Reviewed by Jing Wu, Nanjing Childrens Hospital, China Ke Lu, Southern Medical University, China Updates Copyright 2025 Liang, Liang, He, Zhang and Ke
If youre exploring weight loss options in 2025, youve likely heard the buzz around semaglutide
For Ipamorelin , occasional side effects include temporary redness at the injection site or headache
Match durations before comparing percentages
By Application By application, type 2 diabetes mellitus accounted for a share of 76.49% in the GLP-1 receptor agonist market, as GLP-1 receptor agonists are well established within diabetes treatment algorithms, supported by comprehensive reimbursement coverage and extensive real-world clinical utilization